var data={"title":"Ambrisentan: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ambrisentan: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/325569?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ambrisentan-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ambrisentan: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708620\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not administer ambrisentan to a pregnant woman because it may cause fetal harm. Ambrisentan is very likely to produce serious birth defects if used by pregnant women because this effect has been seen consistently when it is administered to animals. Therefore, pregnancy must be excluded before the initiation of treatment. Females of reproductive potential must use acceptable methods of contraception during treatment and for 1 month after treatment. Obtain monthly pregnancy tests during treatment and 1 month after discontinuation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Dispensing program:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risk of embryo-fetal toxicity, females can only receive ambrisentan through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Letairis REMS program.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032853\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Letairis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6772884\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Volibris</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032857\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Endothelin Receptor Antagonist;</li>\n      <li>\n        Vasodilator</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032893\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary arterial hypertension:</b> Oral: Initial: 5 mg once daily, with or without tadalafil; at 4-week intervals, as tolerated and necessary, may increase either the dose of ambrisentan (maximum dose: 10 mg/day) or tadalafil (if used concomitantly).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Dosage adjustment for concomitant therapy: </i>Coadministration with cyclosporine: Ambrisentan dose should not exceed 5 mg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032894\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032895\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild-to-moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032896\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Preexisting impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; exposure may be increased.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate or severe impairment: Use not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild or moderate impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution and monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ALT or AST &gt;3 times ULN at baseline: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Impairment developing during therapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ALT or AST  &gt;5 times ULN: Discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ALT or AST increased with signs/symptoms of hepatic injury or with bilirubin &gt;2 times ULN: Discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ALT or AST &gt;3 times ULN: Discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ALT or AST increased with signs/symptoms of hepatic injury or with bilirubin &gt;2 times ULN: Discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">May consider reinitiation after ALT or AST levels normalize and if there are no signs/symptoms of hepatic injury or jaundice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032903\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Letairis: 5 mg, 10 mg [contains fd&amp;c red #40 aluminum lake]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032855\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28842887\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Volibris: 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7885303\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088617.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRl2pZFx3LvVfyshPzOOpbLXQ==&amp;TOPIC_ID=8653\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088617.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032899\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Swallow tablet whole. Do not split, crush, or chew tablets. Administer with or without food. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104428\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032860\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">\n      <b>Pulmonary arterial hypertension: </b>Treatment of pulmonary artery hypertension (PAH) (World Health Organization [WHO] Group I) to improve exercise ability and delay clinical worsening; in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. Studies establishing effectiveness included predominantly patients with WHO Functional Class II to III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> According to treatment guidelines from the Fifth World Symposium on Pulmonary Hypertension (WSPH), only a small number of PAH patients with WHO-FC IV symptoms (ie, severely ill patients) were included in clinical trials, therefore, most experts consider ambrisentan second-line therapy in these patients (WSPH [Gail&egrave; 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22120172\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Letaris, a formerly marketed Dutch brand name product for letrozole, may be confused with Letairis, a US brand name for ambrisentan.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032869\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Peripheral edema (14% to 38%), flushing (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache (34%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Dyspepsia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Oligospermia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Decreased hemoglobin (7% to 10%; dose-dependent), anemia (7%), decreased hematocrit</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Nasal congestion (6% to 16%), cough (13%), bronchitis (4%), sinusitis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Cardiac failure, dizziness, fatigue, fluid retention, hypersensitivity, hypotension, increased liver enzymes, nausea, vomiting, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032865\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pregnancy; idiopathic pulmonary fibrosis, including idiopathic pulmonary fibrosis with pulmonary hypertension (WHO Group 3)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to ambrisentan or any component of the formulation; severe hepatic impairment (with or without cirrhosis); ALT or AST &gt;3 times ULN at baseline; breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032866\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention/peripheral edema: Development of peripheral edema due to treatment and/or disease state (pulmonary arterial hypertension) may occur; a higher incidence is seen with concomitant use of tadalafil and in elderly patients. There have also been postmarketing reports of fluid retention requiring treatment (eg, diuretics, fluid management, hospitalization). Further evaluation may be necessary to determine cause and appropriate treatment or discontinuation of therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic changes: A reduction in hematocrit/hemoglobin may be observed within the first few weeks of therapy with subsequent stabilization of levels. Hemoglobin reductions &gt;15% have been observed in some patients. Measure hemoglobin prior to initiating therapy, at 1 month, and periodically thereafter. Significant decreases in hemoglobin in the absence of other causes may warrant the discontinuation of therapy. Use not recommended in patients with clinically significant anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Increases in serum liver aminotransferases have been reported during postmarketing use; however, in the majority of the cases, alternative causes of hepatotoxicity could be identified. Perform liver enzyme testing when clinically indicated. Discontinue therapy if signs/symptoms of hepatic injury appear, if serum liver aminotransferases &gt;5 times ULN (US labeling) or &gt;3 times ULN (Canadian labeling) are observed, or if aminotransferases are increased in the presence of bilirubin &gt;2 times ULN.  Hepatotoxicity has been reported with other endothelin receptor antagonists (eg, bosentan); however, ambrisentan may be tried in patients that have experienced asymptomatic increases in liver enzymes caused by another endothelin receptor antagonist after the liver enzymes have returned to normal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Spermatogenesis: Sperm count may be reduced in men during treatment (as observed with bosentan). No changes in sperm function or hormone levels have been noted. Fertility issues may require discussion with patient. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use caution in patients with mild hepatic impairment; ambrisentan exposure may be increased. The US labeling does not recommend use in patients with moderate or severe impairment. The Canadian labeling recommends use with caution in moderate impairment with monthly monitoring of ALT/AST during therapy and contraindicates use in severe hepatic impairment (with or without cirrhosis) and in patients with ALT or AST &gt;3 times ULN at baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary veno-occlusive disease (PVOD): Discontinue in any patient with pulmonary edema suggestive of PVOD.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy:<b> [US Boxed Warning]: May cause birth defects; use in pregnancy is contraindicated. Exclude pregnancy prior to initiation of therapy and obtain pregnancy tests monthly during treatment and for 1 month after therapy is complete. Reliable contraception must be used during therapy and for 1 month after stopping treatment.</b> Two reliable methods of contraception (eg, hormone method with a barrier method or two barrier methods) must be used throughout treatment and for one month after stopping treatment.  Patients who have undergone a tubal ligation or the insertion of a contraceptive implant or intrauterine device (Copper T 380A or LNg 20) do not require additional contraceptive measures.  A missed menses or suspected pregnancy should be reported to a healthcare provider and prompt immediate pregnancy testing. Women should also be educated on the appropriate use of emergency contraception if failure of contraceptive is known or suspected or in the event of unprotected sex.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Letairis REMS  Program: [US Boxed Warning]: Because of the high likelihood of teratogenic effects, ambrisentan is only available through the Letairis REMS restricted distribution program. Female patients (regardless of reproductive potential), prescribers, and pharmacies must be registered with and meet conditions of the program. Call 1-866-664-5327 or visit www.letairisrems.com for more information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032876\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1, UGT1A3, UGT1A9, UGT2B7; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032875\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8653&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of Ambrisentan. Management: Limit ambrisentan dose to 5 mg/day and monitor for ambrisentan adverse reactions in patients receiving systemic cyclosporine.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032861\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032862\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: May cause birth defects; use in pregnancy is contraindicated. Exclude pregnancy prior to initiation of therapy and obtain pregnancy tests monthly during treatment and for 1 month after therapy is complete. Reliable contraception must be used during therapy and for 1 month after stopping treatment.</b> Based on animal studies, ambrisentan is likely to produce major birth defects if used by pregnant women. Two reliable methods of contraception (eg, hormone method with a barrier method or 2 barrier methods) must be used throughout treatment and for 1 month after stopping treatment. Patients who have undergone a tubal ligation or the insertion of a contraceptive implant or intrauterine device (Copper T 380A or LNg 20) do not require additional contraceptive measures. A missed menses or suspected pregnancy should be reported to a healthcare provider and prompt immediate pregnancy testing. Sperm counts may be reduced in men during treatment (as observed with bosentan). Women with pulmonary arterial hypertension are encouraged to avoid pregnancy (McLaughlin 2009; Taichman 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20520923\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ambrisentan is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the US labeling recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. The Canadian labeling contraindicates use in nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032901\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for significant peripheral edema and evaluate etiology if it occurs; hepatic enzyme testing when clinically appropriate. The Canadian labeling recommends hepatic function testing at baseline then as clinically indicated (all patients) and monthly during therapy (patients with moderate impairment or other risk factors [eg, significant right heart failure, preexisting hepatic disease or previously elevated transaminases, concurrent medications known to increase transaminases]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A woman of childbearing potential must have a negative pregnancy test prior to the initiation of therapy, monthly during treatment, and 1 month after stopping treatment. Hemoglobin and hematocrit should be measured at baseline, at 1 month, and periodically thereafter (generally stabilizes after the first few weeks of treatment). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032882\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks endothelin receptor subtypes ET<sub>A</sub> and ET<sub>B</sub> on vascular endothelium and smooth muscle. Stimulation of ET<sub>A</sub> receptors, located primarily in pulmonary vascular smooth muscle cells is associated with vasoconstriction and cellular proliferation. Stimulation of ET<sub>B</sub> receptors, located in both pulmonary vascular endothelial cells and smooth muscle cells is associated with vasodilation,  antiproliferative effects, and endothelin clearance. Although ambrisentan blocks both ET<sub>A</sub> and ET<sub>B</sub> receptors, the affinity is greater for the ET<sub>A</sub> receptor (&gt;4,000-fold higher affinity).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5032884\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4, CYP2C19, and uridine 5'-diphosphate glucuronosyltransferases (UGTs) 1A9S, 2B7S, and 1A3S; <i>in vitro</i> studies also suggest it is a substrate of organic anion transporting polypeptides (OATP) 1B1 and 1B3 and P-glycoprotein (P-gp) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: ~2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily nonrenal</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324139\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Letairis Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (10): $3,701.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (10): $3,701.83</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6875347\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ambrisan (BD);</li>\n      <li>Endobloc (IN);</li>\n      <li>Volebris (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Volibris (AT, AU, BE, CH, CN, CO, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HK, HR, HU, IE, IL, IS, IT, JP, KR, LT, LU, LV, MT, MY, NL, NO, NZ, PL, PT, RO, SE, SG, SI, SK, TR, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gali&egrave; N, Badesch D, Oudiz R, et al, &ldquo;Ambrisentan Therapy for Pulmonary Arterial Hypertension,&rdquo; <i>J Am Col Cardiol</i>, 2005, 46(3):529-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ambrisentan-drug-information/abstract-text/16053970/pubmed\" target=\"_blank\" id=\"16053970\">16053970</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gali&egrave; N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. <i>J Am Coll Cardiol</i>. 2013;62(25 Suppl):D60-D72. doi: 10.1016/j.jacc.2013.10.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ambrisentan-drug-information/abstract-text/24355643/pubmed\" target=\"_blank\" id=\"24355643\">24355643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Langleben D, &ldquo;Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension,&rdquo; <i>Clin Chest Med</i>, 2007, 28(1):117-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ambrisentan-drug-information/abstract-text/17338931/pubmed\" target=\"_blank\" id=\"17338931\">17338931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Letairis (ambrisentan) [prescribing information]. Foster City, CA: Gilead; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association,&rdquo; <i>J Am Coll Cardiol</i>, 2009, 53(11):1573-619.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ambrisentan-drug-information/abstract-text/19389575/pubmed\" target=\"_blank\" id=\"19389575\">19389575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <i>Chest</i>. 2014;146(2):449-475. doi: 10.1378/chest.14-0793.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ambrisentan-drug-information/abstract-text/24937180/pubmed\" target=\"_blank\" id=\"24937180\">24937180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vatter H and Seifert V, &ldquo;Ambrisentan, a Non-peptide Endothelin Receptor Antagonist,&rdquo; <i>Cardiovasc Drug Rev</i>, 2006, 24(1):63-76<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ambrisentan-drug-information/abstract-text/16939634/pubmed\" target=\"_blank\" id=\"16939634\">16939634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Volibris (ambrisentan) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8653 Version 126.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708620\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F5032853\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F6772884\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F5032857\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F5032893\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F5032894\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F5032895\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F5032896\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F5032903\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F5032855\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F28842887\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7885303\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5032899\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104428\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F5032860\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F22120172\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F5032869\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F5032865\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5032866\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F5032876\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5032875\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F5032861\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5032862\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20520923\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5032901\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F5032882\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F5032884\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324139\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6875347\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8653|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ambrisentan-patient-drug-information\" class=\"drug drug_patient\">Ambrisentan: Patient drug information</a></li></ul></div></div>","javascript":null}